Literature DB >> 32631819

In Vitro Activity of Tedizolid Compared to Linezolid and Five Other Antimicrobial Agents against 332 Anaerobic Isolates, Including Bacteroides fragilis Group, Prevotella, Porphyromonas, and Veillonella Species.

Ellie J C Goldstein1,2, C Vreni Merriam3, Diane M Citron3.   

Abstract

Tedizolid's anaerobic activity is unappreciated. In this study, it was active against all 332 anaerobic isolates tested at ≤2 μg/ml except Bilophila wadsworthia and was more active than linezolid against Bacteroides fragilis group species (MIC90, 1 μg/ml versus 2 to 4 μg/ml). Tedizolid was active against Gram-positive anaerobes (MIC90 for clostridia, 0.25 to 1 μg/ml; MIC90 for anaerobic cocci, ≤0.06 to 0.25 μg/ml). Our data coupled with clinical reports indicate that clinicians should consider its use in mixed infections where Staphylococcus aureus and anaerobes are involved.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Bacteroides fragilis; Prevotella spp.; Veillonella spp.; anaerobes; linezolid; tedizolid

Mesh:

Substances:

Year:  2020        PMID: 32631819      PMCID: PMC7449201          DOI: 10.1128/AAC.01088-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Tedizolid: a new oxazolidinone antimicrobial.

Authors:  Jamie J Kisgen; Hanine Mansour; Nathan R Unger; Lindsey M Childs
Journal:  Am J Health Syst Pharm       Date:  2014-04-15       Impact factor: 2.637

2.  National hospital survey of anaerobic culture and susceptibility methods: III.

Authors:  Ellie J C Goldstein; Diane M Citron; Pamela J Goldman; Ronald J Goldman
Journal:  Anaerobe       Date:  2008-01-11       Impact factor: 3.331

3.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.

Authors:  Dennis L Stevens; Alan L Bisno; Henry F Chambers; E Patchen Dellinger; Ellie J C Goldstein; Sherwood L Gorbach; Jan V Hirschmann; Sheldon L Kaplan; Jose G Montoya; James C Wade
Journal:  Clin Infect Dis       Date:  2014-07-15       Impact factor: 9.079

4.  Safety and Tolerability of More than Six Days of Tedizolid Treatment.

Authors:  Mireia Mensa Vendrell; Maria Tasias Pitarch; Miguel Salavert Lletí; Eva Calabuig Muñoz; Laura Morata Ruiz; Genís Castells Lao; Ester López Suñé; Jose Mensa Pueyo; Maria Rosa Oltra Sempere; Maria-Luisa Pedro-Botet Montoya; Valentina Isernia; Esteban Alberto Reynaga Sosa; Leonor Moreno Nuñez; Juan Pasquau Liaño; Sergio Sequera Arquelladas; José Ramón Yuste Ara; Alex Soriano Viladomiu
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

5.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

6.  Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.

Authors:  Philippe Prokocimer; Carisa De Anda; Edward Fang; Purvi Mehra; Anita Das
Journal:  JAMA       Date:  2013-02-13       Impact factor: 56.272

7.  In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.

Authors:  Ronda Schaadt; Debora Sweeney; Dean Shinabarger; Gary Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

8.  The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.

Authors:  Ellie J C Goldstein; Diane M Citron; Kerin L Tyrrell; Elisa S Leoncio; C Vreni Merriam
Journal:  Anaerobe       Date:  2016-10-03       Impact factor: 3.331

9.  Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents.

Authors:  Diane M Citron; Ellie J C Goldstein; C Vreni Merriam; Benjamin A Lipsky; Murray A Abramson
Journal:  J Clin Microbiol       Date:  2007-07-03       Impact factor: 5.948

10.  Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.

Authors:  Ingrid Wybo; Dorien Van den Bossche; Oriane Soetens; Evilien Vekens; Kristof Vandoorslaer; Geert Claeys; Youri Glupczynski; Margareta Ieven; Pierrette Melin; Claire Nonhoff; Hector Rodriguez-Villalobos; Jan Verhaegen; Denis Piérard
Journal:  J Antimicrob Chemother       Date:  2013-09-05       Impact factor: 5.790

View more
  1 in total

Review 1.  Antibiotic Resistance and Mechanisms of Pathogenic Bacteria in Tubo-Ovarian Abscess.

Authors:  Huanna Tang; Hui Zhou; Runju Zhang
Journal:  Front Cell Infect Microbiol       Date:  2022-07-27       Impact factor: 6.073

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.